<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02680379</url>
  </required_header>
  <id_info>
    <org_study_id>2016-1177</org_study_id>
    <nct_id>NCT02680379</nct_id>
  </id_info>
  <brief_title>Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome</brief_title>
  <acronym>LovaMiX</acronym>
  <official_title>A Pilot Study Exploring the Safety and Synergistic Effect of a Minocycline/Lovastatin Combined Treatment on the Behavior of Individuals With Fragile X Syndrome; Validation of New Biochemical and Neurophysiological Markers (LovaMiX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FRAXA Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Lovastatin, Minocycline and the combination
      Lovastatin/Minocycline are effective in treating behavioral symptoms in Fragile X
      individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline Aberrant Behavior Checklist-Community (ABC-C) total score at 8,12 and 20 weeks</measure>
    <time_frame>baseline, 8 weeks, 12 weeks, 20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale improvement (CGI-I)</measure>
    <time_frame>baseline, 8 weeks, 12 weeks, 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Social Responsiveness Scale (SRS) at 8 and 20 weeks</measure>
    <time_frame>baseline, 8 weeks, 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety, depression and mood scale (ADAMS), change from baseline to 8 and 20 weeks</measure>
    <time_frame>baseline, 8 weeks, 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavior Rating Inventory of Executive Function (BRIEF)</measure>
    <time_frame>Before treatment and at the end of treatment (weeks 20)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Vineland II; adaptive behaviour scale at 20 weeks</measure>
    <time_frame>baseline, 20 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>(optional) Change in brain activity using Functional Magnetic Resonance Imaging (fMRI) at 8 and 20 weeks</measure>
    <time_frame>baseline, 8 weeks, 20 weeks</time_frame>
    <description>fMRI is a non-invasive method of assessing brain activity by detecting signal changes in blood flow and oxygenation known as BOLD (Blood-Oxygen-Level Dependent) contrast imaging.</description>
  </other_outcome>
  <other_outcome>
    <measure>(optional) Change in neurochemistry using Transcranial Magnetic Stimulation (TMS) at 8 and 20 weeks</measure>
    <time_frame>baseline, 8 weeks, 20 weeks</time_frame>
    <description>Using an unpainful magnetic stimulation on the primary motor cortex, TMS will be used to assess intracortical facilitation and inhibition, corresponding respectively to glutamate and GABAergic processes.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Fragile X Syndrome</condition>
  <arm_group>
    <arm_group_label>Minocycline, then Minocycline/Lovastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take minocycline then a combined treatment of minocycline/lovastatin for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lovastatin, then Minocycline/Lovastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will lovastatin then a combined treatment of minocycline/lovastatin for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline, then Minocycline/Lovastatin</intervention_name>
    <description>Participants of this group will take 1 tablet of minocycline 50mg daily for 4 weeks, minocycline 100mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40mg for the following 12 weeks.</description>
    <arm_group_label>Minocycline, then Minocycline/Lovastatin</arm_group_label>
    <other_name>Minocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovastatin, then Minocycline/Lovastatin</intervention_name>
    <description>Participants of this group will take 1 tablet of lovastatin 20 mg daily for 4 weeks, lovastatin 40 mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40 mg for the following 12 weeks.</description>
    <arm_group_label>Lovastatin, then Minocycline/Lovastatin</arm_group_label>
    <other_name>Mevacor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Molecular diagnosis of fragile X syndrome

          -  The participant must be accompanied his parent, legal tutor or legal representative.

          -  Identify a caregiver who spends at least six hours per day with the participant (may
             be the parent, legal tutor, legal representative or an other person).

          -  IQ &lt; 70

          -  ABC-C score &gt; 20

          -  CGI-Severity score ≥ 4

        Exclusion Criteria:

          -  Pregnant or breastfeeding participants

          -  Previous intolerance/allergy to statins, minocycline or tetracyclines

          -  Participants who have taken lovastatin or minocycline in the last 12 weeks

          -  Personal history of myopathy, myalgia or high creatine kinase (CK) levels

          -  Renal disease / liver disease / disturbed hepatorenal tests

          -  Participants taking more than three psychoactive medications (except anticonvulsants)

          -  Untreated or uncontrolled hypothyroidism

          -  Any other active medical condition

          -  Modification of psychoactive treatment in the last 6 weeks prior to randomization

          -  Participants under the age of 13 years who have incomplete formation of the crown of
             their teeth (except possibly their 3rd molars) as shown by panorex

          -  Concomitant use of prohibited drugs

               -  Prohibited drugs include other hypolipemic including gemfibrozil (or other
                  fibrates) and niacin (nicotinic acid), angiotensin converting enzyme (ACE),
                  cyclosporine, danazol, amiodarone, verapamil and inhibitors P450 (CYP3A4)
                  (itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin,
                  inhibitors of HIV protease and nefazodone).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Corbin, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fragile X Clinic, Centre de recherche du CHUS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Recherche du CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>January 25, 2016</study_first_submitted>
  <study_first_submitted_qc>February 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2016</study_first_posted>
  <last_update_submitted>October 10, 2018</last_update_submitted>
  <last_update_submitted_qc>October 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Francois Corbin</investigator_full_name>
    <investigator_title>Dr Francois Corbin, MD, PHD, FRCPC</investigator_title>
  </responsible_party>
  <keyword>Fragile X Syndrome</keyword>
  <keyword>Autism</keyword>
  <keyword>FMR1</keyword>
  <keyword>FRAXA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fragile X Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
    <mesh_term>Lovastatin</mesh_term>
    <mesh_term>L 647318</mesh_term>
    <mesh_term>Dihydromevinolin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

